BofA raised the firm’s price target on Bunge (BG) to $112 from $95 and keeps a Buy rating on the shares, citing updated earnings forecasts and confidence in synergy realization from the Viterra deal. The firm, which assumes that most of the synergy capture will be materialized by yearend 2027 and market dynamics will improve, raised its 2026-27 EPS forecasts to $8.35 and $10.70, respectively.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BG:
- Bunge Global’s Strong Earnings Growth Potential and Strategic Transformation Drive Buy Rating
- Bunge upgraded to Overweight from Equal Weight at Barclays
- Bunge Global SA Reports Mixed Q3 2025 Results
- Bunge Global Sa’s Mixed Earnings Call Highlights
- Bunge backs FY25 adjusted EPS view $7.30-$7.60, consensus $7.27